🚀 VC round data is live in beta, check it out!
Chengdu Easton Valuation Multiples
Discover revenue and EBITDA valuation multiples for Chengdu Easton and similar public comparables like Vir Biotechnology, Harmony Biosciences, Granules India, Celltrion Pharm and more.
Chengdu Easton Overview
About Chengdu Easton
Chengdu Easton Biopharmaceuticals Co Ltd is engaged in research and development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The company's products range from Active Pharmaceutical Ingredient to finish dosage forms like capsules, tablets and injections, enabling us to take R&D discovery to industrial level, solving problems during the course of R&D, production and distribution. Its products are categorized under Active Pharmaceutical Ingredients and Fixed Dose Formulation.
Founded
2009
HQ
Employees
N/A
Website
Financials (LTM)
EV
$2B
Chengdu Easton Financials
Chengdu Easton reported last 12-month revenue of $203M and EBITDA of $60M.
In the same LTM period, Chengdu Easton generated $152M in gross profit, $60M in EBITDA, and $43M in net income.
Revenue (LTM)
Chengdu Easton P&L
In the most recent fiscal year, Chengdu Easton reported revenue of $198M and EBITDA of $50M.
Chengdu Easton expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $203M | XXX | $198M | XXX | XXX | XXX |
| Gross Profit | $152M | XXX | $148M | XXX | XXX | XXX |
| Gross Margin | 75% | XXX | 75% | XXX | XXX | XXX |
| EBITDA | $60M | XXX | $50M | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 25% | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 17% | XXX | XXX | XXX |
| Net Profit | $43M | XXX | $35M | XXX | XXX | XXX |
| Net Margin | 21% | XXX | 18% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Chengdu Easton Stock Performance
Chengdu Easton has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Chengdu Easton's stock price is $9.80.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.0% | XXX | XXX | XXX | $0.20 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialChengdu Easton Valuation Multiples
Chengdu Easton trades at 7.5x EV/Revenue multiple, and 25.2x EV/EBITDA.
EV / Revenue (LTM)
Chengdu Easton Financial Valuation Multiples
As of April 20, 2026, Chengdu Easton has market cap of $2B and EV of $2B.
Equity research analysts estimate Chengdu Easton's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chengdu Easton has a P/E ratio of 39.9x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 7.5x | XXX | 7.7x | XXX | XXX | XXX |
| EV/EBITDA | 25.2x | XXX | 30.6x | XXX | XXX | XXX |
| EV/EBIT | 32.0x | XXX | 43.9x | XXX | XXX | XXX |
| EV/Gross Profit | 10.0x | XXX | 10.3x | XXX | XXX | XXX |
| P/E | 39.9x | XXX | 49.5x | XXX | XXX | XXX |
| EV/FCF | — | XXX | 71.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Chengdu Easton Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Chengdu Easton Margins & Growth Rates
Chengdu Easton's revenue in the last 12 month grew by 14%.
Chengdu Easton's rule of 40 is 45% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chengdu Easton's rule of X is 66% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Chengdu Easton Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 30% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 14% | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 66% | XXX | XXX | XXX |
| S&M Expenses to Revenue | 34% | XXX | 31% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | 14% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 16% | XXX | 20% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 59% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Chengdu Easton Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Chengdu Easton | XXX | XXX | XXX | XXX | XXX | XXX |
| Vir Biotechnology | XXX | XXX | XXX | XXX | XXX | XXX |
| Harmony Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Granules India | XXX | XXX | XXX | XXX | XXX | XXX |
| Celltrion Pharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Hualan Biological Vaccine | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Easton M&A Activity
Chengdu Easton acquired XXX companies to date.
Last acquisition by Chengdu Easton was on XXXXXXXX, XXXXX. Chengdu Easton acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Chengdu Easton
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialChengdu Easton Investment Activity
Chengdu Easton invested in XXX companies to date.
Chengdu Easton made its latest investment on XXXXXXXX, XXXXX. Chengdu Easton invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Chengdu Easton
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Chengdu Easton
| When was Chengdu Easton founded? | Chengdu Easton was founded in 2009. |
| Where is Chengdu Easton headquartered? | Chengdu Easton is headquartered in China. |
| Is Chengdu Easton publicly listed? | Yes, Chengdu Easton is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Chengdu Easton? | Chengdu Easton trades under 688513 ticker. |
| When did Chengdu Easton go public? | Chengdu Easton went public in 2020. |
| Who are competitors of Chengdu Easton? | Chengdu Easton main competitors are Vir Biotechnology, Harmony Biosciences, Granules India, Celltrion Pharm. |
| What is the current market cap of Chengdu Easton? | Chengdu Easton's current market cap is $2B. |
| What is the current revenue of Chengdu Easton? | Chengdu Easton's last 12 months revenue is $203M. |
| What is the current revenue growth of Chengdu Easton? | Chengdu Easton revenue growth (NTM/LTM) is 14%. |
| What is the current EV/Revenue multiple of Chengdu Easton? | Current revenue multiple of Chengdu Easton is 7.5x. |
| Is Chengdu Easton profitable? | Yes, Chengdu Easton is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chengdu Easton? | Chengdu Easton's last 12 months EBITDA is $60M. |
| What is Chengdu Easton's EBITDA margin? | Chengdu Easton's last 12 months EBITDA margin is 30%. |
| What is the current EV/EBITDA multiple of Chengdu Easton? | Current EBITDA multiple of Chengdu Easton is 25.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.